Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Boston Scientific Corp receives CE Mark approval for REBEL platinum chromium coronary stent system


Wednesday, 12 Mar 2014 06:41pm EDT 

Boston Scientific Corp:Receives CE Mark approval for REBELplatinum chromium coronary stent system, the company's latest generation bare metal stent for the treatment of coronary artery disease (CAD).REBEL stent system offers physicians the same stent platform as Promus PREMIER drug eluting stent (DES) but without the everolimus drug. 

Company Quote

12.41
-0.01 -0.08%
19 Sep 2014